Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
about
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
P2860
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@en
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@nl
type
label
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@en
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@nl
prefLabel
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@en
Efficacy and Safety of Guselku ...... : A Randomized Clinical Trial.
@nl
P2093
P2860
P1433
P1476
Efficacy and Safety of Guselku ...... s: A Randomized Clinical Trial
@en
P2093
Keiichiro Hirose
Masamoto Murakami
Satomi Kobayashi
Yukari Okubo
P2860
P304
P356
10.1001/JAMADERMATOL.2017.5937
P407
P577
2018-03-01T00:00:00Z